Catheter Precision (NYSEAMERICAN:VTAK) Announces Earnings Results

Catheter Precision (NYSEAMERICAN:VTAK) released its quarterly earnings data on Friday. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($19.00) by $18.08, FiscalAI reports. The company had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $2.00 million. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%.

Catheter Precision Trading Down 3.4%

Shares of NYSEAMERICAN VTAK traded down $0.01 during trading hours on Friday, reaching $0.28. The stock had a trading volume of 673,619 shares, compared to its average volume of 4,579,099. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.35. The firm has a market cap of $1.01 million, a price-to-earnings ratio of -0.02 and a beta of -1.00. The business’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $1.05. Catheter Precision has a 52-week low of $0.23 and a 52-week high of $4.31.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the SEC. 20.34% of the stock is owned by hedge funds and other institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.